Short answer
Maze Therapeutics, Inc. (MAZE) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$48M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$48M
- −59.4% YoY · −7.2% QoQ
- EPS (diluted)
- −$0.80
- −29.0% YoY · −3.9% QoQ
Source: XBRL data from the Maze Therapeutics, Inc. (MAZE) Q3 2026 10-Q on SEC EDGAR. USD.
Maze Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY; nine-month license revenue $20.0M vs $0
- Operating margin -107.3% vs -112.9% YoY, based on operating losses of $51.5M and $33.0M
- MZE829 R&D spending $7.1M, MZE782 $5.6M, up $2.8M and $3.5M YoY
- Cash, equivalents and marketable securities $477.0M; operating cash use $87.0M for nine months
- Outlook: additional capital needed; MZE782 PKU data expected 2027 and MZE829 pivotal trial planned first half 2027
Risk Factors
- Newly emphasized supply-chain risk: BIOSECURE Act signed December 2025 could restrict WuXi relationships if designated a biotechnology company of concern
- Regulatory risk: CMS GLOBE model begins January 1, 2027, potentially requiring incremental Medicare Part B rebates tied to international prices
- Clinical risk: MZE782 Phase 2 PKU trial initiated August 2026, with topline data expected in 2027
- Operational risk: MZE829 pivotal trial planned first half of 2027, subject to regulatory feedback
- Financial risk: $477.0 million cash, cash equivalents and marketable securities expected to fund operations for at least one year
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Maze Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.